Products & Services

Mapol Webinar Series

Mapol Inc. hosts continuing education (C.E.) Institute accredited, no-cost educational webinars on topics related to health conditions, employee benefits plan designs, environmental trends and emerging new drugs. Our webinars are designed for the educational needs of individuals who work in the Canadian benefits field. These events are privately held, closed-door sessions with attendance granted on an invitation and pre-approval basis only.

Mapol Inc. is now into its 12th year providing more than 80 webinars and C.E. credits from the Institute (IAFE) to those in the health benefits field. Thank you to all who have continued to attend these unique events over the years.

Sign up now to receive invitations to our webinars. Please note, Mapol's webinars are limited to invited stakeholders including benefits consultants and brokers, insurers, PBMs, TPAs, and employers (HR professionals).

Upcoming Webinars

  • 'Pulmonary Arterial Hypertension: Advancements in Diagnosis and Treatment' (Register now)
  • 'Treatment Options for Generalized Myasthenia Gravis (gMG) for Plan Members in Canada' (Register now)
  • 'New Vaccine Coverage Research and Claims Data Trends' (Register now)

Recently Held Webinars

  • 'The Evolution of Insulin Pumps: The latest tubeless and waterproof technology!'
  • 'An Overview of Drug Pooling in Canada: Administration, Costs, and Impacts of Rare Disease Drugs'
  • 'An Inhaled Therapy Option for Pain Management in Gynecology and Urology Procedures'
  • 'Understanding Generalized Myasthenia Gravis (gMG) and the Unmet Medical Need for Patients in Canada'
  • 'Suffering in Silence: The Stigma and Impact of Menopause in the Workplace'
  • 'Vitiligo: More Than What Is Seen'
  • 'A new therapeutic option for Canadians living with Developmental and Epileptic Encephalopathies: LGS, Dravet and TSC'
  • 'Beyond Bias: Advancing Obesity Treatment Coverage for Enhanced Patient Care'
  • 'Private Drug Plan Leadership: Vaccine Coverage Report Card 2023'
  • 'Navigating the Challenges of Living with Crohn's Disease and Ulcerative Colitis'
  • 'Cannabis and Anti-Seizure Medications: Addressing Unmet Needs in Rare, Treatment-Resistant Epilepsies'
  • 'RSV Vaccination: Safeguarding Employee Health and Business Bottom Line'
  • 'A New Treatment Option for Musculoskeletal Injuries to Improve Workplace Disability Management Programs'
  • 'Shining a Light on Epilepsy: Understanding the Challenges to Managing Epilepsy and the Patient Experience'
  • 'The Modern Cancer Patient in the Workplace: the Urgent Need to Cover Genetic Tests to Determine Appropriate Treatments'
  • 'What Does the Recently Announced National Strategy for Drugs for Rare Diseases Mean for Private Drug Plans?'
  • 'Drug Plan Considerations for Prevention of Respiratory Syncytial Virus (RSV) Disease in Infants'
  • 'New Solutions to Redefine Fertility and Family Building Benefits in Private Payer Plans' Watch Recording
  • 'Caring for ALS: New Therapeutic Options and How to Support Plan Members and Caregivers'
  • 'ANCA Associated Vasculitis: An Autoimmune Disease that Affects Small Blood Vessels'
  • 'Generalized Pustular Psoriasis (GPP) - Understanding a Rare Dermatology Disease'
  • 'Vaccines in Group Benefits Plans: Current Gaps, Claims Data, and Access to Coverage'
  • 'Creating a Sustainable Insurance Model for High Cost / Rare Disease Drugs in Canada'
  • 'What Can Private Payers Learn from the Health Canada HTA Aligned Review?'
  • 'Perspectives on Cost Containment Strategies Used in Drug Plans'
  • 'Branded vs Generic Medications in Mental Health'
  • 'Access to Medicines and the Evolving Benefits Plan Landscape'
  • 'The Importance of Supporting Plan Members with Access to Vaccines for Preventable Diseases'
  • 'Considerations for an Inclusive and Sustainable National Drug Funding Model for Rare Disease Drug Treatments'
  • 'Digital Health Transformation in Private Payer Plans - Trends, Access, and an ALS Patient's Perspective'
  • 'An Overview of the Quebec Drug Insurance Pooling Corporation (QDIPC): Administration, Costs, and Potential Application at a National Scale' 
  • 'A New Treatment Option for Soft Tissue Injuries That Reduces Pain and Restores Function'
  • 'Developing More Inclusive Benefits in 2021 - Why Fertility Benefits Matter'
  • 'Drug Plan Considerations for Plan Sponsors - Treatment Differences for Women with Plaque Psoriasis'
  • 'The Liability of High Cost Specialty Drug Coverage Decisions'
  • 'Innovations in Asthma Management: 2020 and Beyond'
  • 'Drug Plan Learnings and Considerations for Drugs for Rare Diseases Post COVID-19'
  • 'Enhancing Contraceptive Access in Canada: The Contraceptive Implant'
  • 'Managing Drugs for Rare Diseases (DRD)'
  • 'Newer Paradigms in Treating the Multiple Dimensions of Insomnia in the Workplace'
  • 'Disease Burden in Migraine and the Evolving Standard of Care in Canada'
  • 'Gene Therapy: Understanding the What's, When's and Why's' 
  • 'British Columbia Biosimilar Initiative'
  • 'Emerging Therapies to Reduce the Risk of Cardiovascular Events'
  • 'Clinical Trials 101 for Private Drug Plan Decisions'
  • 'Original and Similar Biologics: How Healthcare Professionals Can Support Patient Choice'
  • 'Managing Addictions in the Workplace'
  • 'Scratching the Surface: Understanding Adolescent Eczema’s Burden on Patients and their Caregivers'
  • 'Understanding the Burden and High Unmet Need in ALS: Advancements in the Last 20 Years'
  • 'Biosimilars: The Canadian Experience to Date & Future Considerations'
  • 'Group Insurance Advisors Concerns 2019 and Beyond'
  • 'Navigating Life with Inflammatory Bowel Disease (IBD): Combining Digital and Drug Therapy'
  • 'Sustainable Patient-Centred Access to Original and Similar Biologics'
  • 'If You Have Lungs, You Can Get Lung Cancer: The Unexpected Faces of Lung Cancer and New Treatment Options'
  • 'Medical Cannabis Integration on Private Payer Plans'
  • 'Opioid Addiction in Canada - Understanding Current Treatment Options and Preparing for the Future'
  • 'New Clinical Guidelines from Diabetes Canada: Patient-centred Diabetes Care and Chronic Disease Management'
  • 'Gaining Control of Atopic Dermatitis: First Biologic Treatment Targeting IL-4 and IL-13'
  • 'EveryBODY Matters – Coverage of Obesity Treatments in Private Payer Plans'
  • 'Diabetes Management in the Digital Age'
  • 'Burden of Chronic Insomnia in the Workplace'
  • 'Perspectives on Biosimilars in Canada'
  • 'Diabetes in the Workplace: Changing the Conversation on Workplace Wellness'
  • 'Understanding the Impact of Irritable Bowel Syndrome with Diarrhea (IBS-D) in the Workplace'
  • 'Demystifying Immuno-Oncology, its Impact on Employees and Private Payer Plans'
  • 'Osteoarthritis of the Knee: A New Dual Treatment Option'
  • 'Medical Marijuana - What do Payers Need to Know?'
  • 'New Pathways to Controlling Asthma and The Patient Experience with Specialty Infusion Clinics' 
  • 'Multiple Sclerosis in the Workplace: an Overview of the Disease, its Management, and the Patient Experience'
  • 'Depression in the Workplace and A New Therapy for Treatment'
  • 'Navigating the System to Access High Cost Drug Therapies - A Patient's Journey'
  • 'An Ounce of Prevention, Rethinking Lifestyle Drugs'

Search

Login